Guggenheim assumed coverage on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a research report released on Thursday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $4.00 price objective on the stock.
EYPT has been the subject of a number of other research reports. HC Wainwright set a $5.00 price objective on Eyepoint Pharmaceuticals and gave the company a buy rating in a research note on Friday, July 12th. Zacks Investment Research lowered Eyepoint Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $4.13.
Shares of NASDAQ EYPT traded up $0.07 during trading on Thursday, reaching $1.87. 926,263 shares of the company traded hands, compared to its average volume of 392,581. The firm’s fifty day simple moving average is $1.43 and its 200 day simple moving average is $1.73. The stock has a market cap of $196.66 million, a P/E ratio of -3.22 and a beta of 1.71. Eyepoint Pharmaceuticals has a 12-month low of $1.19 and a 12-month high of $3.94. The company has a current ratio of 5.46, a quick ratio of 5.31 and a debt-to-equity ratio of 1.75.
Institutional investors have recently made changes to their positions in the stock. Strs Ohio acquired a new stake in Eyepoint Pharmaceuticals in the 2nd quarter worth about $27,000. JPMorgan Chase & Co. acquired a new stake in Eyepoint Pharmaceuticals in the 2nd quarter worth about $28,000. Wells Fargo & Company MN boosted its holdings in Eyepoint Pharmaceuticals by 90.0% in the 2nd quarter. Wells Fargo & Company MN now owns 96,945 shares of the company’s stock worth $159,000 after buying an additional 45,922 shares during the last quarter. Northern Trust Corp boosted its holdings in Eyepoint Pharmaceuticals by 44.9% in the 2nd quarter. Northern Trust Corp now owns 167,434 shares of the company’s stock worth $275,000 after buying an additional 51,919 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Eyepoint Pharmaceuticals by 225.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 149,870 shares of the company’s stock worth $245,000 after buying an additional 103,857 shares during the last quarter. Hedge funds and other institutional investors own 58.62% of the company’s stock.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.
Read More: Trading signals using Bollinger bands
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.